
Martina Amanzio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3594597/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems. Journal of Neuroscience, 1999, 19, 484-494.	1.7	781
2	Response expectancies in placebo analgesia and their clinical relevance. Pain, 2001, 93, 77-84.	2.0	360
3	The Biochemical and Neuroendocrine Bases of the Hyperalgesic Nocebo Effect. Journal of Neuroscience, 2006, 26, 12014-12022.	1.7	359
4	Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain, 2001, 90, 205-215.	2.0	357
5	Somatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia. Journal of Neuroscience, 1999, 19, 3639-3648.	1.7	323
6	Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature Medicine, 2011, 17, 1228-1230.	15.2	248
7	THE NEUROBIOLOGY OF PLACEBO ANALGESIA: FROM ENDOGENOUS OPIOIDS TO CHOLECYSTOKININ. Progress in Neurobiology, 1997, 52, 109-125.	2.8	214
8	A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain, 2009, 146, 261-269.	2.0	199
9	Neurophysiologic assessment of nerve impairment in posterolateral and muscle-sparing thoracotomy. Journal of Thoracic and Cardiovascular Surgery, 1998, 115, 841-847.	0.4	189
10	Potentiation of placebo analgesia by proglumide. Lancet, The, 1995, 346, 1231.	6.3	183
11	Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain, 1997, 71, 135-140.	2.0	183
12	Activation likelihood estimation metaâ€analysis of brain correlates of placebo analgesia in human experimental pain. Human Brain Mapping, 2013, 34, 738-752.	1.9	165
13	The magnitude of nocebo effects in pain: A meta-analysis. Pain, 2014, 155, 1426-1434.	2.0	154
14	Control of Postoperative Pain by Transcutaneous Electrical Nerve Stimulation After Thoracic Operations. Annals of Thoracic Surgery, 1997, 63, 773-776.	0.7	148
15	Unawareness of deficits in Alzheimer's disease: role of the cingulate cortex. Brain, 2011, 134, 1061-1076.	3.7	124
16	Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain, 1998, 74, 205-211.	2.0	123
17	The placebo response: How words and rituals change the patient's brain. Patient Education and Counseling, 2011, 84, 413-419.	1.0	118
18	Inducing placebo respiratory depressant responses in humans via opioid receptors. European Journal of Neuroscience, 1999, 11, 625-631.	1.2	113

MARTINA AMANZIO

#	Article	IF	CITATIONS
19	Pain anticipation: An activation likelihood estimation metaâ€∎nalysis of brain imaging studies. Human Brain Mapping, 2015, 36, 1648-1661.	1.9	113
20	Metaphor comprehension in Alzheimer's disease: Novelty matters. Brain and Language, 2008, 107, 1-10.	0.8	97
21	Postoperative Pain and Superficial Abdominal Reflexes After Posterolateral Thoracotomy. Annals of Thoracic Surgery, 1997, 64, 207-210.	0.7	93
22	Experimental pain processing in individuals with cognitive impairment. Pain, 2015, 156, 1396-1408.	2.0	85
23	Mechanisms of the placebo response. Pulmonary Pharmacology and Therapeutics, 2013, 26, 520-523.	1.1	78
24	The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. Pain, 1998, 75, 313-319.	2.0	70
25	Shared "Core―Areas between the Pain and Other Task-Related Networks. PLoS ONE, 2012, 7, e41929.	1.1	59
26	Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology, 2011, 213, 791-797.	1.5	57
27	Impaired awareness of movement disorders in Parkinson's disease. Brain and Cognition, 2010, 72, 337-346.	0.8	53
28	Impaired Awareness of Deficits in Alzheimer's Disease: The Role of Everyday Executive Dysfunction. Journal of the International Neuropsychological Society, 2013, 19, 63-72.	1.2	50
29	Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. Lancet Regional Health - Europe, The, 2022, 12, 100253.	3.0	46
30	Nocebo vs. Placebo: The Challenges of Trial Design in Analgesia Research. Clinical Pharmacology and Therapeutics, 2015, 97, 143-150.	2.3	44
31	Self-unawareness of levodopa induced dyskinesias in patients with Parkinson's disease. Brain and Cognition, 2014, 90, 135-141.	0.8	34
32	How Do Nocebo Phenomena Provide a Theoretical Framework for the COVID-19 Pandemic?. Frontiers in Psychology, 2020, 11, 589884.	1.1	26
33	Lockdown Effects on Healthy Cognitive Aging During the COVID-19 Pandemic: A Longitudinal Study. Frontiers in Psychology, 2021, 12, 685180.	1.1	26
34	Role of the Cingulate Cortex in Dyskinesias-Reduced-Self-Awareness: An fMRI Study on Parkinson's Disease Patients. Frontiers in Psychology, 2018, 9, 1765.	1.1	25
35	A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. International Psychogeriatrics, 2012, 24, 698-707.	0.6	22
36	Neuropsychological Correlates of Pre-Frailty in Neurocognitive Disorders: A Possible Role for Metacognitive Dysfunction and Mood Changes. Frontiers in Medicine, 2017, 4, 199.	1.2	22

MARTINA AMANZIO

#	Article	IF	CITATIONS
37	Neuropsychological correlates of instrumental activities of daily living in neurocognitive disorders: a possible role for executive dysfunction and mood changes. International Psychogeriatrics, 2018, 30, 1871-1881.	0.6	22
38	A novel framework for understanding reduced awareness of dyskinesias in Parkinson's Disease. Parkinsonism and Related Disorders, 2017, 39, 58-63.	1.1	20
39	Neural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementia. Experimental Gerontology, 2016, 83, 158-164.	1.2	19
40	Executive Dysfunction and Reduced Self-Awareness in Patients With Neurological Disorders. A Mini-Review. Frontiers in Psychology, 2020, 11, 1697.	1.1	19
41	Unawareness of deficits in ischemic injury: Role of the cingulate cortex. Neurocase, 2014, 20, 540-555.	0.2	18
42	Do we Need a New Procedure for the Assessment of Adverse Events in Anti-migraine Clinical Trials?. Recent Patents on CNS Drug Discovery, 2011, 6, 41-47.	0.9	16
43	Unawareness of bipolar disorder: the role of the cingulate cortex. Neurocase, 2015, 21, 438-447.	0.2	15
44	Quantitative EEG Responses to Ischaemic Arm Stress in Migraine. Cephalalgia, 2001, 21, 224-229.	1.8	14
45	Lessons Learned From Nocebo Effects in Clinical Trials for Pain Conditions and Neurodegenerative Disorders. Journal of Clinical Psychopharmacology, 2016, 36, 475-482.	0.7	14
46	Nocebo effects and psychotropic drug action. Expert Review of Clinical Pharmacology, 2015, 8, 159-161.	1.3	12
47	How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic?. Expert Review of Clinical Pharmacology, 2021, 14, 439-444.	1.3	12
48	Are Patients With Schizophrenia Spectrum Disorders More Prone to Manifest Nocebo-Like-Effects? A Meta-Analysis of Adverse Events in Placebo Groups of Double-Blind Antipsychotic Trials. Frontiers in Pharmacology, 2019, 10, 502.	1.6	11
49	A Possible Association Between Executive Dysfunction and Frailty in Patients With Neurocognitive Disorders. Frontiers in Psychology, 2020, 11, 554307.	1.1	11
50	Are Sleep Problems Related to Psychological Distress in Healthy Aging during the COVID-19 Pandemic? A Review. International Journal of Environmental Research and Public Health, 2021, 18, 10676.	1.2	8
51	Pain Anticipation and Nocebo-Related Responses: A Descriptive Mini-Review of Functional Neuroimaging Studies in Normal Subjects and Precious Hints on Pain Processing in the Context of Neurodegenerative Disorders. Frontiers in Pharmacology, 2019, 10, 969.	1.6	7
52	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. Vaccines, 2021, 9, 1179.	2.1	7
53	Investigating Neuroimaging Correlates of Early Frailty in Patients With Behavioral Variant Frontotemporal Dementia: A MRI and FDG-PET Study. Frontiers in Aging Neuroscience, 2021, 13, 637796.	1.7	6
54	The Role of Neuropsychological Factors in Perceived Threat of SARS-CoV-2 in Healthy Ageing. International Journal of Environmental Research and Public Health, 2021, 18, 5847.	1.2	6

MARTINA AMANZIO

#	Article	IF	CITATIONS
55	A novel neurocognitive approach for placebo analgesia in neurocognitive disorders. Experimental Gerontology, 2019, 118, 106-116.	1.2	5
56	Editorial: Nocebo Effects and Their Influence on Clinical Trials and Practice: Modulating Factors in Healthy and Pathological Conditions. Frontiers in Pharmacology, 2020, 11, 100.	1.6	5
57	Corrigendum to "Neural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementia―[Exp. Gerontol. 83 (2016) 158–164]. Experimental Gerontology, 2017, 96, 164-165.	1.2	4
58	Hypothalamicâ€Pituitaryâ€Adrenal Activity in Adverse Events Reporting After Placebo Administration. Clinical Pharmacology and Therapeutics, 2021, 110, 1349-1357.	2.3	4
59	Nocebo and Pain. , 2016, , 117-131.		3
60	Reduced Self-Awareness Following a Combined Polar and Paramedian Bilateral Thalamic Infarction. A Possible Relationship With SARS-CoV-2 Risk of Contagion?. Frontiers in Psychology, 2020, 11, 570160.	1.1	3
61	Nocebo effects and psychotropic drug action - an update. Expert Review of Clinical Pharmacology, 2020, 13, 75-77.	1.3	2
62	Editorial: Physical and Cognitive Frailty in the Elderly: An Interdisciplinary Approach. Frontiers in Psychology, 2021, 12, 698819.	1.1	2
63	Editorial: Unawareness of Illness in Neurological Disorders: A Focussed Neurocognitive Approach Shedding Light on Neuropsychological Deficits and Neural Underpinnings Potential Association. Frontiers in Psychology, 2020, 11, 622576.	1.1	1
64	Nocebo-Prone Behavior Contributes to SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. SSRN Electronic Journal, 0, , .	0.4	1
65	Conceptualizing Placebo as Active Component and Adjunct in Psychological Treatment. , 2016, , .		0
			_

66 Pain in Parkinson Patients. , 2015, , 209-219.

0